Saint-Herblain, France April 16, 2025 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a prominent player in the vaccine industry, is set to make a significant presence at the 25th World Vaccine Congress, scheduled from April 21 to April 24, 2025, at the Walter E. Washington Convention Center in Washington, D.C. Under the leadership of CEO Thomas Lingelbach, key members from Valneva's executive team will engage in a series of events, including a pivotal presentation on IXCHIQ, the first vaccine in the world to receive regulatory approval against chikungunya.

Valneva will also host a booth at the congress exhibition area, specifically at Stand No. 424, where attendees can learn more about their innovative vaccine solutions.

On April 22, from 11:40 AM to 12:20 PM EST, Dr. Hanneke Schuitemaker, Valneva's Chief Scientific Officer, will lead an interactive workshop focusing on Prophylactic Vaccines Against Enteric Diseases and Antimicrobial Resistance. This session aims to highlight the urgent need for new vaccine developments in light of rising antimicrobial resistance.

Later that evening, Valneva will partake in the Vaccine Industry Excellence Awards ceremony, where the company is a finalist for two prestigious categories: the Best Biotech Award and the Best Prophylactic Vaccine Award for VLA15. This vaccine candidate targets Lyme disease and is currently in Phase 3 of its clinical development, developed in partnership with Pfizer.

The following day, on April 23, at 9:40 AM EST, Susanne Eder-Lingelbach, Vice President of Clinical Development at Valneva, will present vital data regarding their chikungunya vaccine, titled: Valneva's Chikungunya Vaccine: Key Data in Support of Licensure and Plans to Confirm Effectiveness. This presentation will provide insights into the extensive research backing the vaccine's efficacy.

Finally, on April 24 at 9:00 AM EST, Dr. Juan Carlos Jaramillo, Valneva's Chief Medical Officer, will participate in a roundtable discussion titled The Urgent Need for Vaccines Against Mosquito-Borne Diseases. He will join experts such as Gabrielle Breugelmans, Director of Epidemiology and Data Science at the Coalition for Epidemic Preparedness Innovations (CEPI), and Trevor Wellington, Director at the Walter Reed Army Institute of Research Clinical Trials Center. The session will be moderated by Sushant Sahastrabuddhe, Deputy Director General of the International Vaccine Institute, focusing on the escalating threat posed by diseases transmitted by mosquitoes.

Understanding Chikungunya

The chikungunya virus (CHIKV) is a mosquito-borne viral infection predominantly spread by infected Aedes mosquitoes. Symptoms include high fever, severe joint and muscle pain, headaches, nausea, fatigue, and rashes. The debilitating joint pain can last for weeks or even years, significantly impacting the quality of life for those affected.

Since its resurgence in 2004, chikungunya has sparked widespread outbreaks globally, with the virus identified in over 110 countries across Asia, Africa, Europe, and the Americas. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas alone. The economic burden of this disease is considerable, and as the mosquito vectors continue to expand their range, the medical and economic impacts are expected to increase. The World Health Organization (WHO) has emphasized that chikungunya represents a major public health risk.

About Valneva SE

Valneva specializes in the development, production, and commercialization of prophylactic vaccines aimed at infectious diseases with significant medical needs. The company adopts a highly specialized approach, leveraging its expertise in various vaccination methods to create vaccines for diseases lacking effective solutions, or where current options can be improved.

With a robust research and development background, Valneva has successfully advanced several vaccines from early research phases to market availability. Currently, Valneva offers three travel vaccines, including the worlds first chikungunya vaccine, alongside other vaccines developed for third parties.

The company's growing commercial revenues support the ongoing development of its vaccine portfolio, which includes the only advanced clinical-stage Lyme disease vaccine candidate, developed in collaboration with Pfizer, along with candidates for Shigellosis, Zika virus, and other global health threats. More information can be found at

For more information, visit

Contact Information

Investors and Media Contacts at Valneva:
Laetitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
Email: laetitia.bachelot-fontaine@valneva.com

Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
Email: joshua.drumm@valneva.com

Media Contacts at CEPI:
Email: press@cepi.net
Phone: +44 7387 055214

Important Notice

This press release contains certain forward-looking statements regarding Valneva's operations, including the progress, timing, outcomes, and completion of research, development, and clinical trials of candidate products, regulatory approvals, and product reviews. Even if the actual results of Valneva are consistent with the forward-looking statements made in this press release, such results or developments may not be indicative of future outcomes. In some instances, you can identify forward-looking statements by terminology such as may, should, expect, anticipate, believe, intend, estimate, aim, target, or similar words. These forward-looking statements are largely based on Valneva's current expectations as of the date of this press release and are subject to a number of known and unknown risks and uncertainties, as well as other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. Notably, Valneva's expectations could be affected by uncertainties related to vaccine development and manufacturing, unexpected clinical trial outcomes, unexpected regulatory actions or delays, general competition, currency fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patents or other intellectual property protections, the cancellation of existing contracts, and the occurrence of any of these events could significantly harm Valneva's business, financial condition, outlook, and operational results. Given these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will be realized. Valneva provides the information contained in this press release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.